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ABSTRACT
Inter-individual differences in toxic symptoms and pharmacokinetics of high-
dose methotrexate (MTX) treatment may be caused by genetic variants in the MTX 
pathway. Correlations between polymorphisms and pharmacokinetic parameters 
and the occurrence of hepato- and myelotoxicity were studied. Single nucleotide 
polymorphisms (SNPs) of the ABCB1, ABCC1, ABCC2, ABCC3, ABCC10, ABCG2, 
GGH, SLC19A1 and NR1I2 genes were analyzed in 59 patients with osteosarcoma. 
Univariate association analysis and Bayesian network-based Bayesian univariate and 
multilevel analysis of relevance (BN-BMLA) were applied. Rare alleles of 10 SNPs 
of ABCB1, ABCC2, ABCC3, ABCG2 and NR1I2 genes showed a correlation with the 
pharmacokinetic values and univariate association analysis. The risk of toxicity was 
associated with five SNPs in the ABCC2 and NR1I2 genes. Pharmacokinetic parameters 
were associated with four SNPs of the ABCB1, ABCC3, NR1I2, and GGH genes, and 
toxicity was shown to be associated with ABCC1 rs246219 and ABCC2 rs717620 using 
the univariate and BN-BMLA method. BN-BMLA analysis detected relevant effects 
on the AUC0-48 in the following SNPs: ABCB1 rs928256, ABCC3 rs4793665, and GGH 
rs3758149. In both univariate and multivariate analyses the SNPs ABCB1 rs928256, 
ABCC3 rs4793665, GGH rs3758149, and NR1I2 rs3814058 SNPs were relevant. These 
SNPs should be considered in future dose individualization during treatment.
INTRODUCTION
Osteosarcoma is one of the most frequent primary 
malignant bone tumors that occurs in childhood [1]. 
Intensive chemotherapy was introduced in the 1970s, 
which significantly improved survival and currently about 
two thirds of patients recover [2]. The treatment aims 
to reduce the initial tumor volume and to eliminate the 
potential of micrometastases [3]. The cytostatic drugs that 
are used in preoperative chemotherapy are doxorubicin, 
cisplatin, ifosphamide, and methotrexate (MTX) [4]. 
MTX, a folic acid antagonist, is used in high dosages to 
treat all osteosarcoma tumors. It penetrates into the cells 
and inhibits the production of metabolites essential for 
the synthesis of nucleotides [5]. MTX is very effective 
in the treatment of osteosarcoma; however, reduced 
elimination may induce side effects such as hepatotoxicity 
and myelotoxicity. Therefore, MTX-serum levels after 
administration are routinely monitored together with 
hepatic and bone marrow function.
There are large inter-individual differences in 
the elimination of MTX and in the severity of the toxic 
symptoms during therapy. There are many influencing 
factors already known and proven, e.g., hydration, 
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pH level of urine, leucovirin dosage, anatomic and 
physiological parameters, and differences in the 
protocol. Beyond these, the individual differences in the 
pharmacokinetics and toxicities are also influenced by 
genetic factors; however, mapping of the significance of 
genetic factors influencing MTX metabolism is still in the 
initial stages. The genetic variants of the relevant genes 
may alter adsorption, distribution, metabolism, as well as 
excretion of the drug, and can lead to these differences 
[6]. A review of Ferrari S showed that effective molecular-
targeted therapies are unlikely to be available in the near 
future due to genomic complexity and the heterogeneity 
of osteosarcoma. Therefore, optimizing the use of the 
current drugs available by personalizing chemotherapy 
treatment is a potential new line for clinical research in 
osteosarcoma [7].
A schematic overview of the intracellular MTX 
pathway with our selected genes is presented in Figure 
1. MTX enters the cell via the solute carrier family 19, 
member 1 (SLC19A1) transporter protein [5]. A frequently 
studied polymorphism of this gene is the 80G>A 
(rs1051266), which leads to an Arg27His exchange in 
the first transmembrane domain and causes an increased 
affinity for folic acid [8]. This SNP is associated with 
the development of severe mucositis in children with 
osteosarcoma [9]. Within the cell, MTX is polyglutamated 
by the enzyme folylpolyglutamate-synthetase (FPGS) to 
its active form, which enters the folic acid cycle. The 
polyglutamated MTX derivatives are hydrolyzed, creating 
the monoglutamated form by gamma-glutamyl-hydrolase 
(GGH) in the lysosome to facilitate elimination [10]. The 
GGH -401C>T (rs3758149) variant enhances promoter 
activity, increasing protein expression. Increased levels of 
GGH lead to a decreased accumulation of polyglutamated 
MTX and MTX-resistance [11]. Free MTX is exported 
from the cell through the ABCC1-5 and ABCG2 
transporters of the ABC (ATP-binding cassette) protein 
family [12]. The ABCB1 transports its substrates towards 
the lumen in the intestines and the blood vessels thus 
preventing adsorption. It participates in excretion, and in 
forming blood-tissue barriers in the hepatocytes and the 
cells of the renal tubules [13]. The clinical response to 
conventional chemotherapy in osteosarcoma is limited 
due to drug resistance, caused by the overexpression of 
ABCB1. A study of an ABCB1/ABCC1 inhibitor found 
that in osteosarcoma cell lines, the inhibitor was able to 
revert the ABCB1/ABCC1-mediated resistance against 
doxorubicin [14]. ABCC1 mainly appears in dividing cells 
and has an explicit barrier function. The primary task of 
this protein is the protection of cells against toxic effects 
and contribution to the barrier function [15]. ABCC2 is 
mainly expressed on the apical surface of hepatocytes, in 
the intestine, and in the proximal tubules of the kidney 
[16]. It plays an important role in eliminating endogenous 
metabolites and xenobiotics. ABCC3 participates in 
biliary and intestinal excretion of organic anions [17]. 
ABCG2 blocks the adsorption of toxic substances in the 
intestine and enhances excretion into the gall bladder [18]. 
Genetic variants in ABC-transporter genes may alter gene 
expression, as well as substrate recognition, activity, and 
function of these proteins [19].
NR1I2, alias SXR (nuclear receptor subfamily 1, 
group I, member 2 or steroid and xenobiotic receptor) gene 
belongs to the nuclear receptor superfamily. The NR1I2 
protein activates the transcription of many other genes that 
participate in the metabolism and secretion of potentially 
harmful xenobiotics, drugs, and endogenous chemical 
compounds. In the development of drug resistance, it 
participates in the regulation of gene transcription [20], 
[21].
The aim of this study was to investigate the 
pharmacokinetics of high-dose MTX treatment and the 
pharmacogenetics, pharmacokinetics, and toxicity of 
chemotherapy.
RESULTS
In our analysis, 551 MTX blocks in 59 patients were 
tested. The genotype and allele frequency of these SNPs 
are summarized in Table 1.
Pharmacokinetics of MTX
The results of the univariate association analysis are 
summarized in Table 2.
Analyzing the half-live of MTX, it seems that the 
presence of a variant allele of ABCG2 rs2231142 (odds 
ratio (OR) = 4.2, 95% confidence interval (CI) = 1.0–17.8, 
p = 0.037) is associated with a longer first half-life of 
MTX (T
α1/2
). Moreover, the presence of the SNPs NR1I2 
rs7643038 (OR = 2.6, 95% CI = 1.2–5.9, p = 0.02) and 
rs3814055 (OR = 2.2, 95% CI = 1.1–5.1, p = 0.03) show 
a positive correlation.
The area under the concentration–time curve was 
also influenced by some SNPs in our population. The 
presence of a variant allele ABCB1 rs9282564 (OR = 4.2, 
95% CI = 0.9–18.2, p = 0.04) was associated with higher 
AUC0-48 values. In the case of the variant allele ABCC3 
rs4793665 (OR = 0.2, 95% CI = 0.1–0.9, p = 0.03), as 
well as the homozygous variant genotype allele ABCC2 
rs3740066 (OR = 0.1, 95% CI = 0.01–0.8, p = 0.01), 
AUC0-48 was lower.
The peak MTX concentrations proved to be higher 
in the presence of the polymorphism ABCB1 rs9282564 
(OR = 8.8, 95% CI = 1.02–75.6, p = 0.02).
For ABCB1 rs9282564, the AUC0-48 of the 
concentration–time curve and the peak concentration were 
higher in patients with the variant allele, compared with 
patients with the homozygous TT genotype.
A higher 48-h MTX concentration value showed a 
correlation with the presence of variant alleles of NR1I2, 
rs3732361 (OR = 2.6, 95% CI = 1.2–5.9, p = 0.01), and 
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rs6785049 (OR = 14.0, 95% CI = 1.8–106.5, p = 0.006) 
SNPs.
Hepatotoxicity and myelotoxicity
The risk of hepatic toxicity was lower in the 
presence of variant alleles of NR1I2 rs3732361 (OR = 0.1, 
95% CI = 0.01–0.7, p = 0.014), rs3814058 (OR = 0.3, 95% 
CI = 0.1–0.7, p = 0.007), and rs6785049 (OR = 0.1, 95% 
CI = 0.01–0.7, p = 0.02) SNPs.
The risk of bone marrow toxicity was higher due 
to a mutation in ABCC2 rs2273697 (OR = 3.3, 95% CI 
= 1.2–9.4, p = 0.02) and lower due to variant alleles of 
ABCC2 rs3740066 (OR = 0.4, 95% CI = 0.2–0.9, p = 
0.02), NR1I2 rs3732361 (OR = 0.1, 95% CI = 0.01–0.7, 
p = 0.013), rs3814058 (OR = 0.3, 95% CI = 0.1–0.7, p = 
0.007), and rs6785049 (OR = 0.09, 95% CI = 0.01–0.7, p 
= 0.01) SNPs.
Bayesian network-based Bayesian univariate 
and multilevel analysis of relevance (BN-BMLA)
Using the univariate BMLA method, we analyzed 
whether the above-mentioned 29 SNPs had any effect 
on the pharmacokinetic factors (AUC0-48, peak MTX 
level, T
α1/2
), as well as the hepatic and bone marrow 
toxicity. This method gives posterior probability values, 
indicating the level of probability that the models confirm 
a strong relationship between the SNP and the analyzed 
variable, taking into consideration relevant information. 
The posterior probability is given in brackets after the 
SNP. The AUC0-48 is likely to be influenced by ABCB1 
Figure 1: Schematic overview of the intracellular methotrexate pathway. Key molecules and derivatives of the pathway are 
denoted as yellow ovals; transporter proteins and regulatory enzymes as blue rectangles. The examined genes are shown in brackets with 
red italics near the name of the encoded proteins. MTX: methotrexate; PG-MTX: methotrexate polyglutamates; DHF: dihydrofolate; 
THF: tetrahydrofolate; FPGS: folylpolyglutamate synthetase; DHFR: dihydrofolate reductase; MTHFR: 5,10-methylenetetrahydrofolate 
reductase; TYMS: thymidylate synthetase; PPAT: phosphoribosyl pyrophosphate amidotransferase; GART: glycinamide ribonucleotide 
formyltransferase; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; GGH: gamma-glutamyl hydrolase; 
SLC19A1: solute carrier family 19, member 1; NR1I2: nuclear receptor subfamily 1, group I, member 2; ABC transporters: ATP-binding 
cassette transporters.
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Table 1: Selected genes and single nucleotide polymorphisms important in the methotrexate pathway
Gene Polymorphism Allele (1/2)
Genotype  
N 11 (%) 1
Genotype  
N 12 (%) 1
Genotype  
N 22 (%) 1
MAF*100 2 
(%)
HWE 3 
(p)
ABCB1 rs1045642 C/T 16 23 15 49 0.27
ABCB1 rs1128503 C/T 16 29 14 48 0.28
ABCB1 rs9282564 A/G 31 10 0 12 0.37
ABCC1 rs4148358 G/A 32 11 2 17 0.42
ABCC1 rs246219 G/A 38 9 1 11 0.59
ABCC1 rs246221 A/G 25 17 5 29 0.42
ABCC1 rs12922588 A/G 20 23 9 39 0.49
ABCC1 rs215060 A/G 28 18 0 20 0.1
ABCC1 rs4148330 A/G 17 22 4 35 0.4
ABCC2 rs2273697 G/A 32 19 2 22 0.68
ABCC2 rs3740066 G/A 23 21 8 36 0.39
ABCC2 rs717620 G/A 28 13 1 18 0.72
ABCC3 rs4793665 T/C 17 30 9 43 0.48
ABCC3 rs2107441 A/G 16 23 6 39 0.61
ABCC3 rs2412333 G/A 23 24 4 31 0.5
ABCC3 rs733392 G/A 21 28 3 33 0.1
ABCC3 rs12602161 A/G 37 14 0 14 0.1
ABCC10 rs1214748 G/A 15 28 5 40 0.12
ABCC10 rs831314 A/G 37 13 2 16 0.53
ABCC10 rs1214752 G/A 19 18 8 38 0.31
ABCG2 rs2231142 C/A 39 13 0 13 0.3
GGH rs3758149 C/T 20 28 7 38 0.56
SLC19A1 rs1051266 A/G 15 27 14 49 0.79
SXR rs7643038 A/G 16 20 9 42 0.55
SXR rs3814055 G/A 18 23 11 43 0.47
SXR rs1054190 G/A 36 12 0 13 0.32
SXR rs3732361 G/A 13 24 9 46 0.72
SXR rs3814058 A/G 25 16 3 25 0.84
SXR rs6785049 A/G 11 29 9 48 0.19
SNP: single nucleotide polymorphisms
MTX: methotrexate.
1 11: homozygous for the first allele, 12: heterozygous; 22: homozygous for the second allele.
2 MAF: Minor allele frequency * 100 (%).
3 HWE: deviation from the Hardy–Weinberg equilibrium (χ2-test).
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Table 2: Relevant p-values of univariate association test between SNPs and target variables
Gene Polymorphism T
α1/2
AUC0-48
Peak
MTX
48 h 
MTX Hepato-toxicity Myeol-toxicity
ABCB1 rs1045642 - - - - - -
ABCB1 rs1128503 - - - - - -
ABCB1 rs9282564 - ↑0.04 ↑0.02 - - -
ABCC1 rs4148358 - - - - - -
ABCC1 rs246219 - - - - - -
ABCC1 rs246221 - - - - - -
ABCC1 rs12922588 - - - - - -
ABCC1 rs215060 - - - - - -
ABCC1 rs4148330 - - - - - -
ABCC2 rs2273697 - - - - - ↑0.02
ABCC2 rs3740066 - ↓0.01 - - - ↓0.02
ABCC2 rs717620 - - - - - -
ABCC3 rs4793665 - ↓0.03 - - - -
ABCC3 rs2107441 - - - - - -
ABCC3 rs2412333 - - - - - -
ABCC3 rs733392 - - - - - -
ABCC3 rs12602161 - - - - - -
ABCC10 rs1214748 - - - - - -
ABCC10 rs831314 - - - - - -
ABCC10 rs1214752 - - - - - -
ABCG2 rs2231142 ↑0.037 - - - - -
GGH rs3758149 - - - - - -
SLC19A1 rs1051266 - - - - - -
SXR rs7643038 ↑0.02 - - - - -
SXR rs3814055 ↑0.04 - - - - -
SXR rs1054190 - - - - - -
SXR rs3732361 - - - ↑0.01 ↓0.014 ↓0.013
SXR rs3814058 - - - - ↓0.007 ↓0.007
SXR rs6785049 - - - ↑0.006 ↓0.02 ↓0.01
“-” no correlation with the number of variant allele and the target variable (p > 0.05).
Direction of the arrow: the presence of the variant allele increases (↑) or decreases (↓) the value of the pharmacokinetic 
target variable or the frequency of the toxicity.
rs9282564 (0.47), ABCC3 rs4793665 (0.31), GGH 
rs3758149 (0.45), and NR1I2 rs3814058 (0.38) (Figure 
2). The peak concentration is likely to be influenced 
by ABCB1 rs9282564 (0.7), ABCC3 rs4793665 (0.6), 
and NR1I2 rs3814058 (0.58). Hepatic toxicity may be 
influenced by ABCC1 rs246219 (0.6), while bone marrow 
toxicity may be influenced by the presence of ABCC2 
rs717620 (0.56) (Figure 2).
In multiple-target variable BMLA analysis, beyond 
all possible inner interrelations of the cluster of the 
target variables (pharmacokinetic and toxicity data) and 
explanatory variables (age, gender, applied dose, duration 
of infusion, and the 29 SNPs), we also examined which 
explanatory variables will have direct relevance for the 
cluster of target variables. A relevant effect for the target 
variable cluster was detected in the case of ABCB1 
rs928256 (0.6) SNP (Figure 3), which affected the AUC0-
48 and also the peak concentration according to univariate 
analysis. Similarly, in case of the ABCC3 rs4793665 
(0.48) and GGH rs3758149 (0.41) SNPs, the influence 
on the area under the curve could also be demonstrated 
using multivariate analysis. In the multivariable BMLA 
analysis, NR1I2 rs3814058 (0.44) may also influence the 
network system of toxicity and pharmacokinetics; using 
the univariate BMLA method, it was found to be related 
to the pharmacokinetic data, and the univariate association 
method showed a correlation with toxicity occurrence.
DISCUSSION
There are inter-individual differences in the 
pharmacokinetics of high-dose MTX treatment, which 
may lead to toxicities. Due to the complex metabolism and 
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Figure 2: Subgraphs of the strongly relevant variables in pharmacokinetics and hepato-and myelotoxicity according 
to the univariate Bayesian network-based Bayesian multilevel analysis of relevance (BN-BMLA). The direction of the 
arrows determines the variable that may produce an effect on the other. Number on the arrow: posterior probability indicating the level of 
probability that the models may confirm a strong relationship between two variables.
Figure 3: Subgraphs of the strongly relevant variables in pharmacokinetics and hepato- and myelotoxicity according 
to the multivariate BN-BMLA. The direction of the arrows determines the variable that may produce an effect on the other. Number 
on the arrow: posterior probability indicating the level of probability that the models may confirm the strong relationship between two 
variables.
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pathway of MTX, there are still several unknown factors 
that are likely to be revealed through further research. 
Genetic variants of genes involved in transport and 
metabolism were analyzed in patients with osteosarcoma 
to study the pharmacogenetics, pharmacokinetics, and 
toxicities of MTX.
Certain factors that distort MTX metabolism are 
already known and proven, such as hydration, pH level 
of urine, leucovirin dosage, anatomic and physiological 
parameters, and differences in the protocol, along with 
many other factors. Beyond these, individual differences 
in pharmacokinetics and toxicity are mainly influenced 
by genetic factors, but the significance of these factors 
regarding their influence in MTX metabolism has yet to 
be determined.
The most frequently studied polymorphism of the 
GGH gene is SNP -401C>T, located in the promoter 
region regulating gene expression. This SNP influenced 
the area below the 48-h curve in our population, identified 
using univariate and multivariate BN-BMLA analysis. 
The polymorphism in the GGH -401C>T promoter and 
the MTX polyglutamate levels in red blood cells were 
studied in patients with rheumatoid arthritis, who were 
treated weekly with low-dose MTX. The probability to 
have a MTXPG3-5 level below the group median was 4.8 
times higher in patients with the GGH-401TT genotype, 
compared with patients with the C allele [22]. The enzyme 
GGH is important in both folate and antifolate metabolism; 
therefore, it is difficult to clearly define its direct role in 
antifolate drug resistance [23]. The influence on folic acid 
metabolism may compensate its effect on MTX [24]. 
The overexpression of the enzyme reduces the effect 
of antifolates, as the cells are unable to accumulate the 
polyglutamated form [22]. However, due to the increased 
GGH activity, folic acid tends to be released faster, which 
may cause an increased sensitivity to antifolates [10]. Cole 
et al. found that the overexpression of the enzyme GGH 
did not provide resistance to short-term MTX exposure 
in cancer cells. As well as affecting MTX metabolism 
and accumulation, the enzyme influences folic acid 
metabolism, which may compensate its effect on MTX 
[24]. The enzyme GGH is evidently important in the folate 
and antifolate metabolism in cells; however it is difficult 
to clearly define its direct role in antifolate drug resistance. 
Nevertheless, the measurements of the levels of GGH may 
provide valuable information in determining the antifolate 
sensitivity of tumors [23].
ABC-transporters are important in drug adsorption, 
distribution, and elimination. Genetic variants of six 
ABC-transporter genes were studied to assess whether 
they have an effect on the pharmacokinetics and toxicity 
of MTX. The AUC0-48 of the concentration–time curve 
and the peak concentration proved to be higher in patients 
with the ABCB1 rs9282564 variant allele, according to 
both the frequentist-based univariate and univariate BN-
BMLA analysis. In our analysis with multiple target 
variables, the studied ABCB1 SNP was also shown to 
have a relevant effect on the target variables combining 
the kinetics and toxicity. The rs9282564 (Asn21Asp) SNP 
of ABCB1 is a missense polymorphism and creates a T>C 
exchange at position 61 within exon 2 of the gene. The 
role of this polymorphism has been studied in connection 
with several drugs, but no reduced drug elimination has 
been observed in rs9282564CC homozygous HeLa cell 
lines [25]. Also, Kimchi-Sarfaty et al. not could detect a 
reduced gene expression in the presence of this variant in 
HeLa cell line [25]. In the literature, there are no studies 
that examine the correlation between this polymorphism 
and the pharmacogenetics of MTX. Sainz et al. studied 
the polymorphism in connection with the formation of 
Figure 4: Treatment of osteosarcoma according to the COSS96 protocol. A: doxorubicin 90 mg/m2; C: carboplatin 4 × 150 mg/
m2; E: etoposid 4 × 150 mg/m2; I: ifosfamide 2 × 3 g/m2; M: high-dose methotrexate 12 g/m2; OP: date of operation; P: cisplatin 120 mg/
m2; 1 bracket = 1 week.
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colorectal tumors and detected a significant association 
between its presence and the risk of colorectal tumors in 
men [26].
The rs4793665 polymorphism of the ABCC3 gene 
was relevant in both univariate and the multivariate 
analyses. It is located in the promoter region of the gene 
and causes a C>T exchange at base-pair-211. ABCC3 was 
studied by sequencing 103 healthy Caucasian individuals, 
searching for genetic variants which may be related to 
the mRNA and protein levels measured in the liver. The 
mRNA level and the protein level of the ABCC3 gene 
did not correlate with each other. However, in individuals 
with the -211TT genotype, the mRNA level of ABCC3 
was significantly lower compared with people with the CC 
and CT alleles. It has also been shown that the presence 
of the polymorphism influences the binding of nuclear 
factors [27]. In patients with juvenile idiopathic arthritis 
treated with MTX, ABCC3 rs4793665 had significant 
effects on the therapeutic response. It could be reached 
more frequently in the presence of the variant allele (T), 
compared with patients with other genotypes [28].
NR1I2, also known as SXR, induces the expression 
of other enzymes or transporters, such as CYP3A4, 
CYP3A5, and ABCB1 [29]. The NR1I2 variant rs3814058 
was shown to be important in all three of the analyses 
in our population, specifically: (1) it influenced the 
risk of bone marrow and liver toxicity using univariate 
frequentist-based analysis and showed a strong relevance 
with the AUC0-48 and with the peak concentration in 
univariate BN-BMLA analysis and (2) it had an influence 
on pharmacokinetic toxicity in multivariate BN-BMLA 
analysis. NR1I2 rs3814058, located in the 3′- untranslated 
region of the gene, causes a T>C base-pair replacement 
at position 42961 UTR, and is poorly documented in the 
literature. In a Scandinavian study, the prognostic role 
of the NR1I2 gene variants were examined in primary 
sclerosing cholangitis; none of the NR1I2 variants were 
a predisposing factor to the disease, but patients with the 
rs3814058 homozygous variant genotype had a lower 
median survival [30]. The P-glycoprotein (ABCB1) 
level was 1.45 times lower in bowel biopsy samples of 
patients with NR1I2 rs3814058 heterozygous genotype 
than in samples of patients with the homozygous wild-
type genotype [21].
Our results show that several genetic variants 
may have an impact on MTX kinetics and toxicity 
Table 3: Main characteristics of the patients and description of the toxicities and pharmacokinetic parameters
Variable
Patients (number) 59
Gender
Male (number) 31
Female (number) 28
Age at diagnosis
Mean (± SD) (years) 13.6 (± 3.2)
Median (range) (years) 14.3 (5.5–18.5)
Risk groups
Standard risk (number) 48
High risk (number) 11
Hepatotoxicity
Grade 1-2 (ASAT, ALAT < 200 U/L) (number) 28
Grade 3-4 (ASAT, ALAT > 200 U/L) (number) 31
Myelotoxicity
Grade 1 (WBC > 3.0 × 10-9/L) (number) 28
Grade 2-4 (WBC < 3.0 × 10-9/L) (number) 29
Myelotoxicity not known (number) 2
Peak MTX Median (range) (µmol/L) 1110 (736–1589)
48-h MTX Median (range) (µmol/L) 0.36 (0.19–1.06)
AUC0-48 Median (range) (µmol/L) 13680 (8904–20002)
T
α1/2
Median (range) (hours) 2.52 (1.9–3.5)
ALAT: Alanine aminotransferase
ASAT: aspartate aminotransferase
AUC 0-48: area under the concentration–time curve 0–48 h
MTX: methotrexate
SD: standard deviation
T
α1/2
: first half-life time of MTX excretion
WBC: white blood cells
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in osteosarcoma patients. The metabolic pathway of 
the metabolism of MTX is very complex; the genetic 
variants may influence several molecules. Identifying 
a single genetic difference is not sufficient for a proper 
prognostic factor of the kinetics and toxicity of MTX. 
To properly understand the role of genetic variation, a 
large prospective study examining the effects of several 
SNPs is recommended. Evaluating the significance of 
pharmacokinetic factors, the epigenetic, posttranslational, 
and biochemical differences of MTX metabolism should 
also be taken into consideration.
MATERIALS AND METHODS
Patients
Our patient population consisted of 59 children 
diagnosed with osteosarcoma between 1988 and 2006 
at the 2nd Department of Pediatrics of Semmelweis 
University. All study subjects were Hungarian. Informed 
consent was requested from the study subjects, or from 
their parents. The study was conducted according to the 
principles expressed in the Declaration of Helsinki and 
was approved by the Hungarian Scientific and Research 
Ethics Committee of the Medical Research Council (ETT 
TUKEB; Case No.:8-374/2009-1018EKU 914/PI/08.). 
Treatment of the patients was based on the COSS-86 
and COSS-96 protocols (Figure 4). MTX was used at a 
dose of 12 g/m2 body surface area, 4–12 times during a 
protocol. The following clinical parameters were collected 
retrospectively from patients’ charts: age at diagnosis; 
gender; classification of patients in risk-groups; serum 
MTX levels measured at 6, 24, 36, and 48 h subsequent to 
the application of MTX; lowest serum total protein; white 
blood cell (WBC) and neutrophil granulocyte numbers; 
highest values of alanine aminotransferase (ALAT); 
aspartate aminotransferase (ASAT); and bilirubin and 
creatinine measured during the first two weeks following 
the MTX treatment. The adverse drug reactions were 
graded according to the Common Terminology Criteria 
for Adverse Events v3.0 (CTCAE).
http://www.eortc.be/services/doc/ctc/ctcaev3.pdf
The following target variables were used to 
describe the pharmacokinetics of MTX: the area under the 
concentration–time curve (AUC0-48), the peak MTX, and 
the 48-h MTX levels. Two half-lives of MTX excretion 
were calculated from the MTX serum levels, according 
to the two-compartment excretion model. The main 
characteristics of the patients and the detailed description 
of the toxicities and pharmacokinetic parameters are 
shown in Table 3.
SNP selection, DNA extraction, and genotyping
DNA was isolated from the blood of children 
with osteosarcoma using Qiagen isolation kits (QIAmp 
DNA Blood Maxi Kit or QIAmp DNA Blood Midi Kit, 
Qiagen, Hilden, Germany). SNPs were selected based on 
the international literature and prioritized on the basis of 
their estimated functionality, using the following order: 
non-synonymous SNPs, SNPs in the promoter and 3′-
UTR (3′-untranslated region) region, synonymous SNPs, 
and intronic SNPs. The minor allele frequency was set at 
>10%. Our goal was to cover every haplotype block in 
the gene defined by the Haploview 4.1 software (http://
www.broad.mit.edu/mpg/haploview/) (Barrett et al., 
2005) with 1 or 2 SNPs. Altogether, 29 single-nucleotide 
polymorphisms of nine genes (ABCB1, ABCC1, ABCC2, 
ABCC3, ABCC10, ABCG2, GGH, SLC19A1, and NR1I2) 
were chosen; detailed information on the selected SNPs 
are shown in Table 1.
SNPs were genotyped using the GenomeLab 
SNPstream genotyping platform (Beckman Coulter), 
according to the manufacturer’s instructions. A detailed 
description of this procedure can be found in our previous 
article [31].
Statistical methods
Allele frequencies were calculated by allele 
counting. The Hardy–Weinberg equilibrium was tested 
using a χ2 goodness-of-fit test with an acceptable cut-off 
value of p ≥ 0.05 (https://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Univariate association analysis was used to 
determine whether the presence of the variant allele of 
SNP associates with an increase or decrease in the value 
of the pharmacokinetic target variable or the frequency 
of the toxicity. The chi-square (χ2) test was applied. The 
statistical tests were performed by IBM SPSS statistical 
software (version 15.1, IBM Corp., Armonk, NY, USA).
BN-BMLA was also used to study the effect of genetic 
background on pharmacokinetics and toxicity. A Bayesian 
network is a probabilistic graphical model that represents 
the conditional dependencies of a set of random variables 
with a directed acyclic graph. It can efficiently describe the 
joint probability distribution of the variables. A node of the 
graph represents a variable, and an edge represents a direct 
dependency between the corresponding variables. The BN-
BMLA method calculates the posterior probability of certain 
structural features of Bayesian networks (e.g., the presence 
of an edge between two variables) learned from the data. 
The current implementation of BN-BMLA deals with only 
discrete variables, therefore continuous pharmacokinetic 
covariates must be discretized first, to include them in 
the BN-BMLA analysis. These variables were discretized 
based on the median of the values [32], [33]. The posterior 
probability of the strong relevance of each SNP with respect 
to the analyzed variable was calculated by the method. A 
relevant relationship was defined when the probability 
was >0.3. The applied method was developed by our 
research team; for further details see the section in the book 
“Probabilistic graphical models for genetics” [34].
Oncotarget9397www.impactjournals.com/oncotarget
CONCLUSIONS
In our pharmacogenetic analysis, we used three 
different statistical methods to identify a correlation 
between the genotype and the clinical data. SNPs 
ABCB1 rs928256, ABCC3 rs4793665, GGH rs3758149, 
and NR1I2 rs3814058 were shown to have a relevant 
effect in both univariate and the multivariate analyses. 
Pharmacokinetic and pharmacogenetic data would allow 
developing a population pharmacokinetic model, which 
could forecast the probable pharmacokinetic parameters 
individually prior to MTX therapy, thus ensuring an 
individual medication dosage for each patient.
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